BR112016001686A2 - Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição - Google Patents

Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição

Info

Publication number
BR112016001686A2
BR112016001686A2 BR112016001686A BR112016001686A BR112016001686A2 BR 112016001686 A2 BR112016001686 A2 BR 112016001686A2 BR 112016001686 A BR112016001686 A BR 112016001686A BR 112016001686 A BR112016001686 A BR 112016001686A BR 112016001686 A2 BR112016001686 A2 BR 112016001686A2
Authority
BR
Brazil
Prior art keywords
vaccine
composition
preparing
birds
immune response
Prior art date
Application number
BR112016001686A
Other languages
English (en)
Other versions
BR112016001686B1 (pt
Inventor
Gerardus Johannes Degen Wilhelmus
Christina Schrier Carla
Original Assignee
Intervet Int Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intervet Int Bv filed Critical Intervet Int Bv
Publication of BR112016001686A2 publication Critical patent/BR112016001686A2/pt
Publication of BR112016001686B1 publication Critical patent/BR112016001686B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A61K39/17—Newcastle disease virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/117—Nucleic acids having immunomodulatory properties, e.g. containing CpG-motifs
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5256—Virus expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/17—Immunomodulatory nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16041—Use of virus, viral particle or viral elements as a vector
    • C12N2710/16043—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2720/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsRNA viruses
    • C12N2720/00011—Details
    • C12N2720/10011—Birnaviridae
    • C12N2720/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18111—Avulavirus, e.g. Newcastle disease virus
    • C12N2760/18134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Virology (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Biochemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

VACINA, MÉTODOS PARA A PREPARAÇÃO DE UMA VACINA, PARA A VACINAÇÃO DE AVES E PARA ACELERAR A RESPOSTA IMUNE EM AVES, COMPOSIÇÃO, USOS DE UMA COMPOSIÇÃO E DE UM AGONISTA DE TLR21, E, AGONISTA DE TLR21. A adição de um oligodesoxinucleotídeo que é um agonista de TLR21 aviário em uma vacina do vetor do Herpesvírus aviário fornece uma aceleração da resposta imune contra o antígeno que é expresso e dispensado pelo vetor do Herpesvírus.
BR112016001686-6A 2013-07-26 2014-07-25 Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição BR112016001686B1 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP13178137 2013-07-26
EP13178137.9 2013-07-26
PCT/EP2014/066023 WO2015011261A1 (en) 2013-07-26 2014-07-25 Acceleration of vector virus induced immune response in avians

Publications (2)

Publication Number Publication Date
BR112016001686A2 true BR112016001686A2 (pt) 2017-09-19
BR112016001686B1 BR112016001686B1 (pt) 2023-02-07

Family

ID=48874196

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112016001686-6A BR112016001686B1 (pt) 2013-07-26 2014-07-25 Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição

Country Status (9)

Country Link
US (1) US9757449B2 (pt)
EP (1) EP3024935B1 (pt)
CN (1) CN105452468B (pt)
AR (1) AR097029A1 (pt)
BR (1) BR112016001686B1 (pt)
ES (1) ES2745275T3 (pt)
PL (1) PL3024935T3 (pt)
RU (1) RU2701805C2 (pt)
WO (1) WO2015011261A1 (pt)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3263129A1 (en) * 2016-06-29 2018-01-03 Ceva Sante Animale Duck enteritis virus and the uses thereof
CN117357642A (zh) 2016-12-14 2024-01-09 勃林格殷格翰动物保健美国公司 表达禽病原体的多种抗原的重组hvt载体及其用途
EP3701032A1 (en) * 2017-12-15 2020-09-02 Bayer Animal Health GmbH Immunostimulatory oligonucleotides
MX2020006343A (es) 2017-12-20 2020-09-03 Intervet Int Bv Diluyente mejorado para vacuna de herpesvirus alfa asociado con celulas.
MA58717A1 (fr) 2020-06-17 2023-06-28 Boehringer Ingelheim Vetmedica Gmbh Vecteurs hvt recombinants exprimant l'hémagglutinine de la grippe et compositions immunogènes, et leur fabrication et leurs utilisations

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5965138A (en) * 1985-09-06 1999-10-12 Syntro Corporation Recombinant chimeric virus and uses thereof
GB8603341D0 (en) 1986-02-11 1986-03-19 Portapax Ltd Foam sheet
AU2001231245A1 (en) * 2000-01-31 2001-08-07 The Regents Of The University Of California Immunomodulatory polynucleotides in treatment of an infection by an intracellular pathogen
CN1810970B (zh) * 2005-01-27 2011-05-18 长春华普生物技术有限公司 含CpG的单链脱氧核苷酸与其疫苗组合物及其应用
MY160201A (en) * 2008-12-09 2017-02-28 Coley Pharm Group Inc Immunostimulatory oligonucleotides
EP2471926A3 (en) 2010-12-30 2012-07-11 Intervet International BV Immunostimulatory oligodeoxynucleotides
BR112013029966A2 (pt) * 2011-05-26 2017-01-31 Intervet Int Bv oligodesoxinucleotídeo imunoestimulatório não metilado, vetor, e, vacina para prevenir ou combater uma doença infecciosa
JP5872684B2 (ja) * 2011-05-26 2016-03-01 インターベット インターナショナル ベー． フェー． 免疫刺激性オリゴデオキシヌクレオチド
RU2593950C2 (ru) 2011-10-21 2016-08-10 Интервет Интернэшнл Б.В. Рекомбинантный непатогенный mdv-вектор, обеспечивающий полиспецифический иммунитет
CA3206983A1 (en) 2011-10-21 2013-04-25 Intervet International B.V. Recombinant non-pathogenic marek's disease virus constructs encoding infectious laryngotracheitis virus and newcastle disease virus antigens
PE20141482A1 (es) * 2011-11-30 2014-11-08 Merial Ltd Vectores recombinantes de hvt que expresan antigenos de patogenos de aves y sus usos

Also Published As

Publication number Publication date
ES2745275T3 (es) 2020-02-28
CN105452468B (zh) 2018-08-21
EP3024935A1 (en) 2016-06-01
AR097029A1 (es) 2016-02-17
CN105452468A (zh) 2016-03-30
BR112016001686B1 (pt) 2023-02-07
EP3024935B1 (en) 2019-07-17
RU2701805C2 (ru) 2019-10-01
WO2015011261A1 (en) 2015-01-29
RU2016106419A (ru) 2017-08-29
US20160158347A1 (en) 2016-06-09
PL3024935T3 (pl) 2020-01-31
US9757449B2 (en) 2017-09-12

Similar Documents

Publication Publication Date Title
BR112018000862A2 (pt) composições de vacina
BR112016010716A8 (pt) dose de reforço imunológico, baixa, de um inibidor de mtor, seu uso, e adjuvante de vacina
BR112016001686A2 (pt) Vacina, método para a preparação de uma vacina, composição, e, uso de uma composição
MX2016016746A (es) Composiciones de vacuna con adyuvante dual, preparacion y usos.
PH12015501716B1 (en) Anti-mycoplasma spp. subunit vaccine
MX359999B (es) Vacunas de virus bovino liquidas estables.
PL3073959T3 (pl) Zespól szczepiący do podawania szczepionki do młodej kury
CL2015001111A1 (es) Composición coadyuvante que comprende un hidrato de carbono unido al quitosano formando una base de schiff; formulación de vacuna que la comprende; método de elaboración; y uso de la vacuna.
BR112016018654A2 (pt) Composições de silicato estabilizadas e seu uso como composições antiperspirantes
BR112017003462A2 (pt) coronavírus bovino atenuado, vacina, e, método de vacinação de um bovino.
NZ630831A (en) Compositions and methods for administration of vaccines against dengue virus
MX2015013832A (es) Composicion de vacuna y metodo de uso.
BR112016022463A2 (pt) método para induzir uma resposta imune em um indivíduo, primeira e segunda composições imunogênicas, e, uso de uma primeira composição imunogênica e de uma segunda composição imunogênica
CL2016003107A1 (es) Vacunas guiadas por anticuerpos y métodos de uso para generar respuestas inmunitarias maduras rápidas
PH12014501795B1 (en) Rotavirus subunit vaccines and methods of making and use thereof
MX2015015428A (es) Eliminacion de riesgo de narcolepsia en vacunas contra influenza.
MX2022007212A (es) Vacuna contra la bronquitis infecciosa.
BR112015018330A2 (pt) cepas de flavobacterium vivas modificadas, vacinas estabilizadas compreendendo as mesmas, e métodos de preparo e uso das mesmas
AR106501A1 (es) Adyuvante y composición de vacuna que lo contiene
BR112017003979A2 (pt) método para a preparação de um antígeno vacinal, vacina susceptível de ser produzida pela implementação do método, e uso de um calixareno
AR089868A1 (es) Vacuna vectorial de eimeria para campylobacter jejuni
CL2013001774A1 (es) Formulacion con actividad inmunoestimulante/adyuvante que comprende alpinona , dimetil sulfóxido y suero fisiológico; uso de dicha formulación para preparar vacunas para vertebrados.
UY35077A (es) Formulaciones farmacéuticas y proceso de producción de formulaciones farmacéuticas
BR112015025257A2 (pt) Complexo imunogênico para uso em vacinação e método para obtenção do mesmo
MX2019015700A (es) Vacuna de subunidades anti-mycoplasma spp.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07G Grant request does not fulfill article 229-c lpi (prior consent of anvisa) [chapter 7.7 patent gazette]

Free format text: NOTIFICACAO DE DEVOLUCAO DO PEDIDO POR NAO SE ENQUADRAR NO ART. 229-C DA LPI.

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 25/07/2014, OBSERVADAS AS CONDICOES LEGAIS